The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial
statements for 2024, and HBC has today published the Annual Report and
Sustainability Report for 2024.
Please find the Annual Report and ESG Report attached.
For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
Hofseth BioCare is a Norwegian consumer and pet health company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability. It upcycles the side streams of the salmon industry by taking
fresh filleted salmon and converting it from a waste product into ingredients to
improve human and pet health. These ingredients are ProGo®, a mix of bioactive
peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid
fractions contained in fish, and CalGo® / NT-II((TM)) salmon bone powder
containing calcium hydroxyapatite and undenatured collagen for bone and joint
health. HBC places scientific evidence at the forefront which has led to
important academic partnerships and the identification of unique health
benefits. This includes the demonstration of improved iron metabolism by
boosting the body's ability to take up and use iron resulting in increased
energy and vitality with ProGo® as well as the activation of the GLP-1 receptor
with fat reduction in overweight adults.
OmeGo® has shown important immune health benefits including recovery from viral
infection and improved respiratory health and sleep in adults troubled by
particulate matter pollution. Finally, CalGo® has shown both bone and joint
health benefits to support healthy ageing and active lifestyles. This work has
also resulted in the granting of several patents protecting these discoveries.
It has also led to the discovery of potential therapeutics and HBC has spun out
a biotech-focused company, HBC Immunology (HBCI). HBCI has raised external
finance, and the lead program is in prostate cancer followed by ovarian cancer.
A separate molecule is targeted as an oral, steroid-sparing therapy for asthma.
This information is subject to disclosure requirements pursuant to section 5-12
of the Norwegian Securities Trading Act.